Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cures 2.0 Would Circumvent CMS’ Pause On Breakthrough Payment Rule, Improve Telehealth, And More

Executive Summary

A new medical research bill proposed by US lawmakers would push through a delayed but highly anticipated CMS policy requiring payment for breakthrough devices.

You may also be interested in...



Consumer Advocacy Group Presses For Cures 2.0 Revisions

Consumer advocacy group Public Citizen wants US lawmakers to amend Cures 2.0 to restore the right of patients to sue medical device manufacturers, among other changes.

Cures 2.0 Throws MCIT A Lifeline, And More

The second 21st Century Cures Act includes a provision to force the US Medicare agency to cover breakthrough medical devices for elderly patients, among other mandates.

Real-World Evidence Deemed Essential For Breakthrough Designations

A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel